Menu Search
Equities

Medicenna Therapeutics Corp

MDNAF:QXE

Medicenna Therapeutics Corp

Actions
  • Price (USD)1.13
  • Today's Change0.072 / 6.81%
  • Shares traded105.76k
  • 1 Year change+263.02%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 20:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-26.68m
  • Incorporated2015
  • Employees16.00
  • Location
    Medicenna Therapeutics Corp2 Bloor St W., 7Th FloorTORONTO M4W 3E2CanadaCAN
  • Phone+1 (416) 648-5555
  • Fax+1 (416) 648-5555
  • Websitehttps://www.medicenna.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.